Q-omics provides the consensus-scored MIR6776 profile across patient tissues and cancer cell-line models. MIR6776 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MIR6776 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, MIR6776 RNA expression shows 6,391 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight THYM, LUSC, and KIRC as cancer lineages where MIR6776 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6776 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6776 survival associations across molecular data types. MIR6776 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6776 RNA expression–survival associations across cancer types. High MIR6776 expression shows unfavorable associations in THYM, KICH, COAD, UVM and OV, but favorable associations in HNSC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MIR6776 RNA expression.
This table summarizes MIR6776 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6776. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6776 shows higher tumor expression in LUSC, HNSC, COAD and CHOL. The LUSC box plot shows higher MIR6776 RNA expression in tumor versus normal tissue (log2 FC = +0.755, t-test p = .024).
This table shows molecular features associated with MIR6776 in patient tissues and cancer cell lines. In patient samples, MIR6776 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
